Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 requires reasonable pricing agreements for biomedical products developed with.

The Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 mandates that entities conducting federally funded research and development of biomedical products enter into agreements with the Secretary of Health and Human Services to ensure reasonable pricing. The act defines "biomedical product or service" as drugs, vaccines, medical devices, and other health care technologies. The Secretary may set additional requirements for reasonable pricing, including mechanisms to lower prices based on revenue targets, cost-effectiveness, or access barriers.

Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 requires reasonable pricing agreements for biomedical products developed with.

The Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 mandates that entities conducting federally funded research and development of biomedical products enter into agreements with the Secretary of Health and Human Services to ensure reasonable pricing. The act defines "biomedical product or service" as drugs, vaccines, medical devices, and other health care technologies. The Secretary may set additional requirements for reasonable pricing, including mechanisms to lower prices based on revenue targets, cost-effectiveness, or access barriers.